



NDA	Product(s)	Proprietary Name	Patent Number	Listing Type
20	1	Incruse Ellipta	8746242	DP
			9333310	DP
			8201556	DP
204275	1,2,3	Breo Ellipta	8161968	DP
			9333310	DP

As the Policy Statement explains, patents improperly listed in the Orange Book may delay lower-cost generic drug competition. By listing their patents in the Orange Book, brand drug companies may benefit from an automatic, 30-month stay of FDA approval of competing

---



---



---

may include investigating this conduct as an unfair method of competition under Section 5 of the FTC Act, 15 U.S.C. § 45, and as

---